Signant Health and Lothar Medical Collaborate on Respiratory Assessment Technology

Philadelphia and Würzburg, Germany, September 5, 2026, Signant Health, a leading provider of evidence generation solutions for clinical trials, and Lothar Medical today announced a strategic collaboration aimed at commercializing Lothar Medical’s next-generation pulmonary function technology, ALDS PRO. The collaboration will integrate Signant’s market-leading electronic clinical outcome assessment (eCOA) solutions with ALDS PRO, an all-in-one respiratory assessment system, to create a comprehensive solution for respiratory studies.

ALDS PRO, an innovative respiratory assessment system, combines three essential components, spirometry, airway oscillometry, and fractional exhaled nitric oxide (FeNO), into a portable, guided system. This integration aims to simplify equipment management, promote consistent data collection, and offer a more streamlined experience for patients. The system is designed to be used alongside spirometry and FeNO, capturing airway mechanics during normal tidal breathing and providing an objective measure of airway inflammation.

“Respiratory development programs require evidence that reflects both the patient's real-life experience and the underlying physiology of disease,” said Roger Smith, CEO of Signant Health. “Our collaboration with Lothar Medical creates a compelling path to bring its innovative pulmonary function technology to clinical research. By combining ALDS PRO with our eCOA solutions, we aim to provide sponsors with a more integrated and accurate way to capture patient-reported, respiratory, and movement-based evidence.”

David Markus Thomas, managing director of Lothar Medical, added, “ALDS PRO was created to make comprehensive pulmonary assessment more accessible and less fragmented. Signant brings the eCOA leadership, digital endpoint expertise, scientific depth, and global clinical trial infrastructure needed to translate that vision into a purpose-built solution for research. This collaboration represents an important step toward making ALDS PRO available to sponsors and sites conducting respiratory trials around the world.”

The companies are also leveraging Signant’s Sensor-Enhanced eCOA (SEE) strategy, which combines patient-reported outcomes with sensor-generated evidence. The SEE approach brings together clinical outcome assessments, wearable-derived digital measures, and validated scientific approaches to provide a unified solution for capturing patient health data in clinical trials.

Signant and Lothar Medical plan to showcase the integrated solution at the European Respiratory Society International Congress 2026, taking place from September 5 to 9 in Barcelona, Spain. The two companies will staff a booth at the Congress to promote the planned partnership and gather feedback from sponsors.

At the congress, attendees can visit Lothar Medical’s booth U.02B to see demonstrations of: - Lothar Medical’s ALDS PRO, which combines forced spirometry, airway oscillometry, and FeNO in a portable system. - Ametris ActiGraph LEAP®, a medical-grade multisensor watch that supports the collection of movement-based digital endpoints and continuous measures of activity, sleep, and mobility.

These demonstrations will illustrate the companies’ shared vision for connecting pulmonary assessments, patient-reported outcomes, and movement-based digital measures to build a more comprehensive picture of patient health in respiratory clinical trials.

Signant Health is the evidence generation company, leveraging software, deep therapeutic and scientific knowledge, and operational expertise to deliver quality evidence across traditional, virtual, and hybrid trial models. For over 25 years, 600+ sponsors and CROs of all sizes, including all Top 20 pharma, have trusted Signant's comprehensive eClinical solutions. Our clinical outcome assessments (eCOA, clinician ratings, cognitive testing) and wearable digital health technologies powered by Ametris provide the industry's most comprehensive evidence generation capabilities, alongside EDC, eConsent, RTSM, supply chain management, and data quality analytics.

Lothar Medical develops respiratory diagnostic technologies designed to make lung assessment faster, more comprehensive, and easier to perform. Its portable ALDS platform combines respiratory measurements with cloud-based analysis to support efficient, multidimensional lung-function assessment. ALDS PRO integrates airway oscillometry, forced spirometry, and FeNO measurement in a single system.

SOURCE: Signant Health